News

STAT20h
FDA approves blockbuster Dupixent for chronic hives
The FDA had rejected the companies’ initial application in 2023, requesting additional data after the pharma firms reported ...
Sanofi-Regeneron's Dupixent gets FDA's nod for skin condition
The U.S. Food and Drug Administration approved the use of Sanofi and Regeneron's blockbuster drug Dupixent for patients with ...
BioPharma Dive3d
Sanofi, Regeneron win FDA nod for Dupixent in chronic hives
The partners overcame an earlier rejection to win a seventh use for Dupixent, though some analysts are skeptical of its sales ...
Fierce Pharma3d
Sanofi, Regeneron score their 7th indication for Dupixent with FDA nod to treat hives condition
On its way to generating sales of $14 billion in just its seventh full year on the market, Sanofi and Regeneron’s Dupixent ...
Regeneron, Sanofi Get FDA Approval For Dupixent in Skin Disease CSU
Regeneron Pharmaceuticals and Sanofi won U.S. Food and Drug Administration expanded approval of their blockbuster anti-inflammatory drug Dupixent for the inflammatory skin condition chronic ...
Regeneron, Sanofi announce FDA approval of Dupixent for CSU
Regeneron Pharmaceuticals (REGN) and Sanofi (SNY) announced that the U.S. Food and Drug Administration has approved Dupixent for the treatment ...